Literature DB >> 31398483

Epidemiology and characterisation of carbapenem-non-susceptible Pseudomonas aeruginosa in a large intensive care unit in Jakarta, Indonesia.

Yulia Rosa Saharman1, Andreu Coello Pelegrin2, Anis Karuniawati3, Rudyanto Sedono4, Dita Aditianingsih4, Wil H F Goessens5, Corné H W Klaassen5, Alex van Belkum6, Caroline Mirande7, Henri A Verbrugh5, Juliëtte A Severin8.   

Abstract

The aim of this study was to describe the epidemiology and clinical impact of carbapenem-non-susceptible Pseudomonas aeruginosa (CNPA) in intensive care units (ICUs) of the national referral hospital of Indonesia. Adult patients admitted to ICUs were prospectively included. Pseudomonas aeruginosa were from clinical cultures and systematic screening. Environmental niches and healthcare workers (HCWs) were also screened. Susceptibility was determined phenotypically and the presence of carbapenemase genes was determined by PCR. Multiple loci variable-number tandem repeat analysis (MLVA) and multilocus sequence typing (MLST) were used for genotyping. Of the patients included in the study, 17/412 (4.1%) carried CNPA on admission and 34/395 (8.6%) became positive during their ICU stay. The acquisition rate was 18/1000 patient-days at risk. Of 16 environmental isolates, 12 (75.0%) were CNPA. HCWs screened negative. Acquisition of CNPA was associated with longer ICU stay (adjusted hazard ratio = 1.89, 99% confidence interval 1.12-3.13). Mortality was >40% among patients with CNPA versus <30% among those without CNPA (P = 0.019). Moreover, 83/119 (69.7%) CNPA carried either blaVIM (n = 36), blaIMP (n = 23) or blaGES-5 (n = 24). Four sequence types (STs) dominated (ST235, ST823, ST446 and ST357). Five major MLVA clusters were distinguished, two belonging to ST235 and the other three to ST823, ST446 and ST357. CNPA are introduced into these ICUs and some strains expand clonally among patients and the environment, creating endemic CNPA. VIM-, IMP- and GES-5 genes are prevalent. CNPA acquisition was associated with prolonged ICU stay and may affect ICU survival.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carbapenemase; Indonesia; Intensive care unit; Metallo-β-lactamase; Microbial drug resistance; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2019        PMID: 31398483     DOI: 10.1016/j.ijantimicag.2019.08.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Comparative Evaluation of Assays for Broad Detection of Molecular Resistance Mechanisms in Enterobacterales Isolates.

Authors:  J N Brazelton de Cardenas; C D Garner; Y Su; L Tang; R T Hayden
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

Review 2.  The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.

Authors:  Dalal Hammoudi Halat; Carole Ayoub Moubareck
Journal:  Antibiotics (Basel)       Date:  2020-04-16

3.  Evaluation of Empirical Meropenem Bolus Protocol in Pseudomonas aeruginosa: A Three-Year Analysis in Tertiary Intensive Care Unit.

Authors:  I Wayan Suranadi; Putu Agus Surya Panji; Ni Nyoman Sri Budayanti; Tjokorda Gde Agung Senapathi; Arif Budiman Susatya
Journal:  Int J Gen Med       Date:  2021-11-09

4.  Whole Genome Multi-Locus Sequence Typing and Genomic Single Nucleotide Polymorphism Analysis for Epidemiological Typing of Pseudomonas aeruginosa From Indonesian Intensive Care Units.

Authors:  Manisha Goyal; Andreu Coello Pelegrin; Magali Jaillard; Yulia Rosa Saharman; Corné H W Klaassen; Henri A Verbrugh; Juliëtte A Severin; Alex van Belkum
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

5.  High-Risk International Clones of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Endemic to Indonesian Intensive Care Units: Impact of a Multifaceted Infection Control Intervention Analyzed at the Genomic Level.

Authors:  Corné H W Klaassen; Juliëtte A Severin; Andreu Coello Pelegrin; Yulia Rosa Saharman; Aurélien Griffon; Mattia Palmieri; Caroline Mirande; Anis Karuniawati; Rudyanto Sedono; Dita Aditianingsih; Wil H F Goessens; Alex van Belkum; Henri A Verbrugh
Journal:  mBio       Date:  2019-11-12       Impact factor: 7.867

Review 6.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

7.  Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing Pseudomonas aeruginosa.

Authors:  Min-Ge Wang; Zhi-Yong Liu; Xiao-Ping Liao; Ruan-Yang Sun; Run-Bo Li; Yan Liu; Liang-Xing Fang; Jian Sun; Ya-Hong Liu; Rong-Min Zhang
Journal:  Antibiotics (Basel)       Date:  2021-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.